Inhibiteur lupique de la coagulation : Questions médicales fréquentes
Nom anglais: Lupus Coagulation Inhibitor
Descriptor UI:D016682
Tree Number:D23.113.475
Termes MeSH sélectionnés :
Interrupted Time Series Analysis
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteur lupique de la coagulation : Questions médicales les plus fréquentes",
"headline": "Inhibiteur lupique de la coagulation : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteur lupique de la coagulation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-16",
"dateModified": "2025-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteur lupique de la coagulation"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"url": "https://questionsmedicales.fr/mesh/D019774",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"code": {
"@type": "MedicalCode",
"code": "D019774",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.113"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteur lupique de la coagulation",
"alternateName": "Lupus Coagulation Inhibitor",
"code": {
"@type": "MedicalCode",
"code": "D016682",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thomas Schmitz",
"url": "https://questionsmedicales.fr/author/Thomas%20Schmitz",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany."
}
},
{
"@type": "Person",
"name": "Charlotte A Bäuml",
"url": "https://questionsmedicales.fr/author/Charlotte%20A%20B%C3%A4uml",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany."
}
},
{
"@type": "Person",
"name": "Diana Imhof",
"url": "https://questionsmedicales.fr/author/Diana%20Imhof",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. Electronic address: dimhof@uni-bonn.de."
}
},
{
"@type": "Person",
"name": "Jeremy W Jacobs",
"url": "https://questionsmedicales.fr/author/Jeremy%20W%20Jacobs",
"affiliation": {
"@type": "Organization",
"name": "Department of Laboratory Medicine, Yale School of Medicine, 330 Cedar Street, New Haven, CT, 06520, USA. Jeremy.jacobs@yale.edu."
}
},
{
"@type": "Person",
"name": "Jiraphorn Issara-Amphorn",
"url": "https://questionsmedicales.fr/author/Jiraphorn%20Issara-Amphorn",
"affiliation": {
"@type": "Organization",
"name": "Medical Microbiology, Interdisciplinary and International Program, Graduate School, Chulalongkorn University, Bangkok, Thailand."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Impact of the value driven outcomes program among cataract surgery patients in Singapore: an interrupted time series analysis.",
"datePublished": "2023-05-15",
"url": "https://questionsmedicales.fr/article/37189106",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12913-023-09427-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of COVID-19 on epidemic trend of hepatitis C in Henan Province assessed by interrupted time series analysis.",
"datePublished": "2023-10-17",
"url": "https://questionsmedicales.fr/article/37848842",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12879-023-08635-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of implementing a free varicella vaccination policy on incidence in Wuxi City, China: an interrupted time series analysis.",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37469289",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1017/S0950268823001152"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Impact of the COVID-19 Pandemic and Lockdowns on Self-Poisoning and Suicide in Sri Lanka: An Interrupted Time Series Analysis.",
"datePublished": "2023-01-19",
"url": "https://questionsmedicales.fr/article/36767200",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20031833"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of national COVID-19 restrictions on incidence of notifiable communicable diseases in England: an interrupted time series analysis.",
"datePublished": "2022-12-12",
"url": "https://questionsmedicales.fr/article/36510205",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12889-022-14796-0"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"item": "https://questionsmedicales.fr/mesh/D019774"
},
{
"@type": "ListItem",
"position": 4,
"name": "Inhibiteur lupique de la coagulation",
"item": "https://questionsmedicales.fr/mesh/D016682"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteur lupique de la coagulation - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteur lupique de la coagulation",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteur lupique de la coagulation",
"description": "Comment diagnostiquer un inhibiteur lupique de la coagulation ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels sont les signes cliniques associés ?\nLe diagnostic nécessite-t-il des antécédents médicaux ?\nPeut-on avoir un inhibiteur sans lupus ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Interrupted+Time+Series+Analysis&page=7#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteur lupique de la coagulation",
"description": "Quels sont les symptômes courants ?\nLes symptômes varient-ils d'une personne à l'autre ?\nY a-t-il des symptômes spécifiques aux femmes ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?\nPeut-on avoir des symptômes sans saignement ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Interrupted+Time+Series+Analysis&page=7#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteur lupique de la coagulation",
"description": "Peut-on prévenir l'inhibiteur lupique ?\nQuels conseils de mode de vie peuvent aider ?\nLes femmes enceintes doivent-elles être surveillées ?\nY a-t-il des vaccinations recommandées ?\nComment gérer le stress pour prévenir les symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Interrupted+Time+Series+Analysis&page=7#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteur lupique de la coagulation",
"description": "Quels traitements sont disponibles ?\nLes anticoagulants sont-ils toujours nécessaires ?\nY a-t-il des effets secondaires aux traitements ?\nLe traitement est-il à vie ?\nLes traitements sont-ils efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Interrupted+Time+Series+Analysis&page=7#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteur lupique de la coagulation",
"description": "Quelles sont les complications possibles ?\nLes complications sont-elles fréquentes ?\nComment prévenir les complications ?\nLes complications peuvent-elles être graves ?\nY a-t-il des signes d'alerte pour les complications ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Interrupted+Time+Series+Analysis&page=7#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteur lupique de la coagulation",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?\nLe stress peut-il être un facteur de risque ?\nY a-t-il des facteurs environnementaux ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Interrupted+Time+Series+Analysis&page=7#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un inhibiteur lupique de la coagulation ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par des tests de coagulation et la détection d'anticorps spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de temps de céphaline activée (TCA) et les tests d'anticorps anti-cardiolipine sont courants."
}
},
{
"@type": "Question",
"name": "Quels sont les signes cliniques associés ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des saignements anormaux et des thromboses, souvent sans cause apparente."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il des antécédents médicaux ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de lupus ou d'autres maladies auto-immunes sont importants."
}
},
{
"@type": "Question",
"name": "Peut-on avoir un inhibiteur sans lupus ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est possible d'avoir un inhibiteur lupique sans diagnostic de lupus, bien que rare."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des saignements, des ecchymoses, et des douleurs thoraciques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la nature des symptômes peuvent varier considérablement entre les individus."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux femmes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes peuvent éprouver des symptômes liés à la grossesse, comme des complications thromboemboliques."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent s'aggraver, surtout sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans saignement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent présenter des symptômes thromboemboliques sans saignement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'inhibiteur lupique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Quels conseils de mode de vie peuvent aider ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles être surveillées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance étroite est nécessaire pour prévenir les complications pendant la grossesse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccinations recommandées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations doivent être discutées avec un médecin, surtout pour les immunodéprimés."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pour prévenir les symptômes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de gestion du stress, comme la méditation, peuvent aider à réduire les symptômes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des anticoagulants et des immunosuppresseurs pour gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les anticoagulants sont-ils toujours nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, leur nécessité dépend de la gravité des symptômes et des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent avoir des effets secondaires, comme des saignements ou des infections."
}
},
{
"@type": "Question",
"name": "Le traitement est-il à vie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la réponse au traitement et de l'évolution de la maladie, souvent à long terme."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La plupart des traitements sont efficaces pour contrôler les symptômes et prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des thromboses, des AVC et des problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent survenir, mais leur fréquence dépend de la gestion de la maladie."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement approprié et un suivi régulier peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être graves ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent être graves et nécessiter une intervention médicale urgente."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes d'alerte pour les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques ou des troubles neurologiques doivent alerter immédiatement."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le sexe féminin, des antécédents familiaux et d'autres maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque est plus élevé chez les jeunes femmes, généralement entre 15 et 45 ans."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies auto-immunes augmentent le risque d'inhibiteur lupique."
}
},
{
"@type": "Question",
"name": "Le stress peut-il être un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut exacerber les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains médicaments ou à des agents environnementaux peut être un facteur."
}
}
]
}
]
}
Healthcare cost is increasing rapidly in Singapore. Moving towards a value-based healthcare framework enables a sustainable health system. The National University Hospital (NUH) implemented the Value ...
We conducted an interrupted time-series analysis for cataract surgery episodes between January 2015 and December 2018. Using segmented linear regression models, we estimate the changes in levels and t...
Following VDO program implementation, the total cost of cataract surgery had a significantly decreased by $327.23 (95% CI: -$421.04 to -$233.43; p < 0.01) and the trend significantly decreased by $13....
The VDO program was associated with a reduction in cost without compromising on quality outcomes. The program provides a structured methodology to measure performances, and through these data, initiat...
Hepatitis C presents a profound global health challenge. The impact of COVID-19 on hepatitis C, however, remain uncertain. This study aimed to ascertain the influence of COVID-19 on the hepatitis C ep...
We collated the number of monthly diagnosed cases in Henan Province from January 2013 to September 2022. Upon detailing the overarching epidemiological characteristics, the interrupted time series (IT...
Between January 2013 and September 2022, a total of 267,968 hepatitis C cases were diagnosed. The yearly average diagnosis rate stood at 2.42/100,000 persons. While 2013 witnessed the peak diagnosis r...
The measures undertaken to curtail COVID-19 led to a diminishing trend in the diagnosis rate of hepatitis C. The ARIMA model is a useful tool for evaluating the impact of large-scale interventions, be...
Varicella vaccination is optional and requires self-payment. On 1 December 2018, Wuxi City launched a free varicella vaccination program for children. This study aimed to evaluate the changes in varic...
Evidence from high-income countries suggests that the impact of COVID-19 on suicide and self-harm has been limited, but evidence from low- and middle-income countries is lacking. Using data from a hos...
Non-pharmaceutical interventions (NPIs), such as travel restrictions, social distancing and isolation policies, aimed at controlling the spread of COVID-19 may have reduced transmission of other endem...
An interrupted time series analysis was conducted to examine whether NPIs was associated with trends in endemic communicable diseases, using weekly reported cases of seven notifiable communicable dise...
Following the introduction of COVID-19 restrictions, there was an 81.1% (95% CI; 77.2-84.4) adjusted percentage reduction in the total number of notifiable diseases recorded per week in England. The g...
A total reduction in the incidence of endemic notifiable diseases was observed in England following the implementation of public health measures aimed at reducing transmission of SARS-COV-2 on March 2...
The objective of this research was to evaluate the effect of implementing a system-level tiered huddle system (THS) on the reporting of patient safety events into the official event reporting system....
A quasi-experimental study using interrupted time series was conducted to assess the impact and changes to trends in the reporting of patient safety events pre- (February-July 2020; six months) and po...
The system-level THS implementation led to a significant and immediate increase in the total number of patient safety events reported per month (777.73, 95% confidence interval [CI] 310.78-1,244.68, p...
These findings suggest that system-level THS implementation may increase reporting of patient safety events in the official event reporting system....
The purpose of this study was to investigate the change in the incidence rate, length of hospital stay (LOS), in-hospital mortality rate, and surgical method of hip fractures during the coronavirus di...
We calculated the expected values of the incidence of hip fractures, in-hospital mortality and LOS of hip fracture patients in 2020 (COVID period) based hip fracture database of the Korean National He...
The overall incidence rate of hip fracture in 2020 was not significantly different from the expected value (PC, -5%; 95% CI, -13 to 4;...
In 2020, the incidence rate of hip fracture did not significantly decrease, and in-hospital mortality rate did not significantly increase compared to the expected rates, which were projected based on ...
COVID-19 was responsible for many deaths and economic losses around the globe since its first case report. Governments implemented a variety of policies to combat the pandemic in order to protect thei...
Shortages of nurses and unequal distribution of nursing staff have been huge challenges for global health services....
The aim of our study was to evaluate the impact of the National Nursing Development Plan on nursing human resources in China....
An interrupted time series design was used in this study. The data for this study were extracted from the National Health Statistics Yearbook from 1978 to 2021. The Ministry of Health issued the Natio...
Interrupted time series analysis showed that after the implementation of the National Nursing Development Plan (2005-2010), the building of nurses in China was gradually strengthening, and the number ...
The implementation of the National Nursing Development Plan has greatly expanded the scale of nursing human resources in China and significantly optimized the efficiency of allocation. The implementat...
The implementation of the National Nursing Development Plan has greatly expanded the scale of nursing human resources in China and significantly optimized the efficiency of allocation....
In September 2019, the "4 + 7" centralized procurement pilot program was expanded nationwide aiming at reducing drug prices by means of volume-based procurement and using accredited generic drugs for ...
A single-group interrupted time series was applied using drug purchase data, covering 25 months from December 2018 to December 2020. Drugs related to the centralized procurement policy were selected a...
After the implementation of the policy, a significant increase was associated with the volume of bid-winning drugs (p < 0.001) and the volume of generic and branded drugs decreased immediately. The DD...
These findings indicated that the policy demonstrated positive effects in terms of price reductions and cost savings and accelerated the substitution of generics against branded drugs. The "patent cli...